TABLE 2.
Use of specific ART treatments by U.S. and non-U.S. residents, 2006–2013, n (%).
| U.S. residents | Non-U.S. residents | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ART treatment | < 35 y (n = 469,771) | 35–37 y (n = 251,408) | 38–40 y (n = 236,927) | 41–42 y (n = 123,497) | >42 y (n = 129,469) | All ages (n = 1,211,072) | < 35 y (n = 5,303) | 35–37 y (n = 3,784) | 38–40 y (n = 4,333) | 41–42 y (n = 2,978) | >42 y (n = 7,374) | All ages (n = 23,772) |
| Oocyte donor cycles | 13,967 (3.0) | 12,385 (4.9) | 21,452 (9.1) | 21,804 (17.7) | 59,085 (45.6) | 128,693 (10.6) | 842 (15.9) | 869 (23.0) | 1,348 (31.1) | 1,441 (48.4) | 5,635 (76.4) | 10,135 (42.6) |
| Gestational carrier cycles | 5,578 (1.2) | 3,634 (1.5) | 3,686 (1.6) | 2,076 (1.7) | 4,941 (3.8) | 19,915 (1.6) | 511 (9.6) | 447 (11.8) | 522 (12.1) | 416 (14.0) | 1,050 (14.2) | 2,946 (12.4) |
| PGD/PGS cycles | 13,735 (4.5) | 8,774 (5.6) | 9,123 (6.2) | 4,647 (6.1) | 3,684 (5.4) | 39,963 (5.3) | 910 (24.9) | 590 (23.9) | 508 (18.4) | 261 (14.8) | 512 (13.2) | 2,781 (19.1) |
| ICSI cycles | 240,635 (75.5) | 120,326 (74.0) | 112,772 (73.7) | 57,746 (73.3) | 54,004 (74.8) | 585,483 (74.6) | 3,074 (81.7) | 2,078 (80.6) | 2,362 (81.3) | 1,562 (83.8) | 3,622 (85.5) | 12,698 (82.8) |
Note: The percentages of oocyte donor and gestational carrier cycles were calculated among all ART cycles (shown in column headers). The percentages of cycles using PGD/PGS and ISCI techniques were calculated among 797,211 (PGD/PGS) and 826,153 (ICSI) cycles for which these fields were reported, because PGD/PGS and ICSI status were not collected for frozen and cancelled cycles. ART = assisted reproductive technology; PGD = preimplantation genetic diagnosis; PGS = preimplantation genetic screening; ICSI = intracytoplasmic sperm injection.
Levine. ART use in the U.S. by nonresidents. Fertil Steril 2017.